1. Rosiglitazone attenuates hypoxia-induced renal cell apoptosis by inhibiting NF-κB signaling pathway in a PPARγ-dependent manner
- Author
-
Jun-Yu, Wei, Miao-Yue, Hu, Xiu-Qi, Chen, Feng-Ying, Lei, Jin-Shuang, Wei, Jie, Chen, Xuan-Kai, Qin, and Yuan-Han, Qin
- Subjects
Male ,NF-kappa B ,Apoptosis ,Epithelial Cells ,General Medicine ,Kidney ,Critical Care and Intensive Care Medicine ,Rats ,Rosiglitazone ,PPAR gamma ,Rats, Sprague-Dawley ,Proto-Oncogene Proteins c-bcl-2 ,Nephrology ,Animals ,Hypoglycemic Agents ,Thiazolidinediones ,RNA, Messenger ,Hypoxia ,bcl-2-Associated X Protein ,Signal Transduction - Abstract
In recent years, peroxisome proliferator-activated receptor γ (PPARγ) has been found to be closely associated with hypoxia renal disease. The aim of this study was to investigate the relationship between rosiglitazone and mitochondrial apoptosis in renal tissue and its associated mechanisms.Twenty-four male Sprague-Dawley rats were randomly divided into three groups (The results showed that compared with the normal control group, the renal tissue of rats after hypoxia was severely damaged, as shown by massive renal tubular epithelial cell degeneration and detachment, and renal tubular dilation. The NF-κB protein expression significantly increased, the Bcl-2 protein and mRNA expression significantly decreased, and Bax protein and mRNA expression significantly increased (Rosiglitazone can alleviate hypoxia renal injury, with the possible mechanism involving attenuation of apoptosis by inhibiting the activation of the NF-κB signaling pathway in a PPARγ-dependent manner and increasing Bcl-2 and decreasing Bax expression.
- Published
- 2022